Study to Compare Conivaptan Pharmacokinetics in Subjects With Mild & Moderate Kidney Function Impairment to Subjects With Normal Kidney Function

Inclusion Criteria: * Weighs at least 45 kg * Body mass index between 18 and 40 kg/m2 inclusive * Must be in good health other than renal function impairment and related stable diseases for the renal impaired subjects * Must have a screening and pre-dose estimated glomerular filtration rate (GFR) that corresponds with the level of renal impairment based on the abbreviated Modification of Diet in Renal Disease (MDRD) formula * Female subject of child-bearing potential must not be pregnant or lactating, must have a negative pregnancy test, utilizes adequate contraceptive methods while in this study or may be surgically sterile and/or two years post menopausal Exclusion Criteria: * Subject is known to be HIV positive or has HIV antibodies * Has clinically significant history or presence of illness, medical condition, or laboratory abnormality * Is Hepatitis positive * Subject with renal impairment has not been on a stable dose of concomitant medications for at least 4 weeks prior to start of study and/or dose changes are likely during the study * History of substance abuse within 6 months prior to screening * Has clinically significant history or presence of psychiatric illness, malignancy, or immunodeficiency syndrome * Has abnormal liver function tests (ALT, AST, and/or bilirubin) * Has had a blood transfusion or donated/lost more than 450ml of blood within 56 days of study drug administration or has donated plasma within 7 days prior to study drug administration